predicting for survival and early molecular remission. Second, CD34 cell dose and NK30, but not day-30 CD3 þ cell count, were predictors of transplant outcome and CD34 cell dose correlated with day-30 NK counts. The conclusion was that higher transplanted CD34 cell doses may improve outcomes by increasing early recovery of NK cells. These observations suggest that GVL activity early after HLA-matched SCT may be exerted more by NK cells than by T cells. However, it is not obvious how such NK cells would exert GVL, since 30 days after transplant most NK cells are likely to be more immunoregulatory than cytotoxic (CD56 bright CD16 cells).
We hypothesize that early NK cells exert non-classical antileukemia activity. We found that interleukin (IL)-2 stimulation of granulocyte colony-stimulating factor-mobilized CD34 þ cells generates NK and myeloid cells with strong cell-to-cell contact antiproliferative activity (but weak cytotoxic activity) against myeloid leukemia cell lines. [10] [11] [12] Kinetic studies have shown that the antiproliferative effect of CD34 þ cells on myeloid cell lines begins about 48 h (data not shown) following IL-2 stimulation, before CD56 antigen acquisition ( Figure 1 ). Thus, we speculate that cytokine-stimulated CD34 þ cells have an inhibitory effect on leukemia proliferation, which is present during IL-2-or IL-15-induced lymphoid and myeloid commitment toward NK cells and early monocytes. This antiproliferative effect may compensate for deficient cytolytic activity against myeloid leukemia cells. It will be of interest to determine whether early recovering NK cells after SCT or after induction chemotherapy possess similar properties and to explore the GVL potential of this cytostatic function. Ando et al.
1 report a case of acute myeloid leukaemia (AML) of donor cell origin following cord blood transplantation. This is the third such recent case. 2, 3 At least two other cases, in Japan and France (S Mizutani and E Gluckman, personal communication), have been observed but as yet unpublished. A similar phenomenon has been recorded previously in more than 20 cases following conventional bone marrow transplantation. 4 In both situations, leukemia of donor cell origin will be underLetters to the Editor estimated, but it appears that this event may be substantially more frequent with a cord blood source of stem cells. There are several potential explanations for leukemogenesis via this unusual route. [1] [2] [3] [4] Perhaps, the most plausible was predicted for cord blood before the recent series of case reports. 5, 6 Systematic screening of a large series of unselected cord blood samples revealed that B1% harboured putative pre-leukaemic clones with TEL-AML1 fusion or B0.2% with AML-ETO. 5 The frequency of such cells in positive cord bloods was of the order of 10 À3 -10 À4 , indicative of a clone size of B10 6 cells in the new born. It was suggested that the clinical use of such 'preleukaemic' samples as a source of stem cells might involve a risk of leukaemia in association with the proliferative stress consequent to transplantation. 5 Several inferences can be drawn from the data. First, if results with these particular fusion genes are typical of prenatal leukemia initiation in general, 7 then something like 5% of cord bloods may contain pre-leukemic clones. Second, the risk of the cord blood donor with such clones developing leukaemia him or herself is very low and of the order of 1%.
These conclusions have implications for how one should respond to the cases of donor 'relapse'. The priority must be to establish the mechanism of donor cell leukaemia. If the above mechanism is at play, then the clear prediction is that cells bearing at least one of the molecular abnormalities found in the 'relapse' leukaemic blasts (i.e. the initiating mutation) would be present and detectable in archived donor cells. This would need to be assessed by carefully controlled reverse transcriptasepolymerase chain reaction plus combined immunophenotypefluorescence in situ hybridization technologies as described. 5 If this turns out to be the case, then there are other issues to be addressed, including additional ethical concerns. 8 Given the B1% risk of leukaemia in the donor, one would not expect to see leukaemia emerging in that individual and one can argue that it would be unethical to inform the donor or the donor's parents. Screening all cord bloods for potential 'contamination' with pre-leukaemic clones might be desirable, but would not be very practical given the wide variety of chromosomal and mutational events that could initiate acute leukaemia. Cord blood transplantation has been a very considerable success 9 and it is unlikely that donor cell leukaemia would seriously compromise its continued use. Nevertheless, there is now some urgency to establish the frequency of donor cell leukaemia by more systematic screening of 'relapse' cases in the EUROCORD project and elsewhere and identifying whether or not this does indeed reflect transfer of pre-leukaemic clones. The genetic basis of this disorder is poorly understood. Cytogenetic abnormalities differ from those commonly reported in other B-cell neoplasms. Translocations involving immunoglobulin heavy-chain gene (IgH) are a common genetic change in multiple myeloma (MM) (75%) and a recurrent abnormality in many B-cell lymphomas such as t(11;14)(q123;q32) in mantle cell lymphoma, t(14;18)(q32;q21) in follicular lymphoma and t(9;14)(p13;q32) in lymphoplasmocytic lymphoma. On the other hand, the incidence of IgH rearrangements is low in WM (o3%).
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1,2 The translocation t(11;18)(q21;q21), a specific abnormality, observed in about 20% of extranodal marginal zone lymphomas has been reported in few cases of patients with WM. 3, 4 However, this translocation was not detected in the tumor cells of 24 WM patients using well-validated probe for its detection. 1 Deletions of chromosome 13q14 are present in approximately 50% of patients with MM or B-cell chronic lymphocytic leukemia (B-CLL), but are rare in WM at the time of diagnosis (o5%) and with a low frequency in patients after treatment (15%). 5 The deletion of the long arm of chromosome 6 is a recurrent abnormality reported in about 50%, in cases of WM mainly in advanced disease and is frequently associated with clonal evolutions ( 1
